EUCTR2015-003759-23-SK进行中（未招募）1 期
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject must have completed Study M13-740 through Week 52.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 96
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •For any reason subject is considered by the investigator to be an unsuitable candidate
- •Female subject with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study.
- •Subject is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)MedDRA version: 18.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2014-005527-27-LVAbbVie Deutschland GmbH & Co. KG220
进行中（未招募）
1 期
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT 494 in Subjects with Crohn's DiseaseCrohn's DiseaseEUCTR2015-003759-23-CZAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's DiseaseMedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856Crohn's DiseaseEUCTR2015-003759-23-NLAbbVie Deutschland GmbH & Co. KG210
进行中（未招募）
1 期
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCrohn's Disease (CD)MedDRA version: 20.0Level: LLTClassification code: 10013099Term: Disease Crohns Class: 10017947CTIS2024-510727-19-00AbbVie Deutschland GmbH & Co. KG33
进行中（未招募）
1 期
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT 494 in Subjects with Crohn's DiseaseMedDRA version: 19.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856Crohn's DiseaseEUCTR2015-003759-23-ESAbbVie Deutschland GmbH & Co. KG210